CEACAM5 and metastatic neoplasm: Current methods for detecting metastatic disease in the clinical setting include those that require the use of specific biomarkers in circulation (e.g., serum), secretions (e.g., urine), or tissue biopsies, such as cancer antigen 15–3 and carcinoembryonic antigen (Figure 5) [36,37].